Get the Stockscreener App
5.06
11.54%
-0.66
Ardelyx Inc stock is traded at $5.06, with a volume of 6.74M.
It is down -11.54% in the last 24 hours and up +3.05% over the past month.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
See More
Previous Close:
$5.72
Open:
$5.73
24h Volume:
6.74M
Relative Volume:
1.56
Market Cap:
$1.20B
Revenue:
$251.85M
Net Income/Loss:
$-72.58M
P/E Ratio:
-16.15
EPS:
-0.3134
Net Cash Flow:
$-63.80M
1W Performance:
-12.61%
1M Performance:
+3.05%
6M Performance:
-20.57%
1Y Performance:
-40.47%
1-Day Range:
$5.05
$5.73
1-Week Range:
$5.05
$6.55
52-Week Range:
$4.32
$9.83
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
5.06 | 1.20B | 251.85M | -72.58M | -63.80M | -0.3134 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
Ardelyx CEO Michael Raab sells $129,124 in company stock By Investing.com - Investing.com Australia
Ardelyx CFO Justin Renz sells $29,076 in stock By Investing.com - Investing.com South Africa
Ardelyx (ARDX) Earnings Call: Strong Growth Amidst Challenges - TipRanks
Ardelyx chief legal officer sells $24,128 in stock By Investing.com - Investing.com South Africa
Ardelyx chief medical officer Laura Williams sells $27,783 in stock - Investing.com India
Ardelyx chief medical officer Laura Williams sells $27,783 in stock By Investing.com - Investing.com Australia
Ardelyx CEO Michael Raab sells $129,124 in company stock - Investing.com
Ardelyx CFO Justin Renz sells $29,076 in stock - Investing.com
Ardelyx Executives Sell Shares to Cover Tax Obligations - TradingView
Ardelyx chief legal officer sells $24,128 in stock - Investing.com
Ardelyx, Inc. (NASDAQ:ARDX) Q4 2024 Earnings Call Transcript - MSN
H.C. Wainwright holds Ardelyx stock at $5.50 target, neutral stance By Investing.com - Investing.com Australia
Ardelyx (NASDAQ:ARDX) Releases Earnings Results, Hits Estimates - MarketBeat
Ardelyx price target lowered to $13 from $15 at Raymond James - TipRanks
H.C. Wainwright holds Ardelyx stock at $5.50 target, neutral stance - Investing.com
Breaking Down Ardelyx: 4 Analysts Share Their Views - Benzinga
Ardelyx Stock Rises After-Hours On Q4 Beat, Drug Sales Outlook: Retail Gets Big Dose Of Optimism - MSN
Ardelyx Inc. Grapples with Trade Secret Risks Threatening Financial Stability - TipRanks
Ardelyx Reports Strong 2024 Financial Performance - TipRanks
Ardelyx: Q4 Earnings Snapshot - mySA
Ardelyx, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
ARDELYX, INC. SEC 10-K Report - TradingView
Ardelyx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Ardelyx Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Earnings call transcript: Ardelyx beats Q4 2024 forecasts, stock dips - Investing.com
Ardelyx Inc earnings beat by $0.01, revenue topped estimates - Investing.com Nigeria
Ardelyx (ARDX) Meets Q4 Earnings Estimates - Yahoo Finance
Earnings Flash (ARDX) Ardelyx Posts Q4 EPS $0.02, vs. FactSet Est of $0.03 -February 20, 2025 at 07:54 am EST - Marketscreener.com
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Can Ardelyx's $334M Revenue and Dual Blockbuster Strategy Transform Biotech Investment? - StockTitan
Shareholders of Ardelyx, Inc. Should Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your RightsARDX - ACCESS Newswire
Ardelyx (NASDAQ:ARDX) Trading Up 7.9%Here's Why - MarketBeat
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Ardelyx's Presentation at TD Cowen Conference Reveal New Growth Catalysts? - StockTitan
Ardelyx, Inc. (NASDAQ:ARDX) Sees Significant Increase in Short Interest - MarketBeat
ARDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ardelyx, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Ardelyx (ARDX) to Release Earnings on Thursday - MarketBeat
Ardelyx director David Mott buys $992,671 in company stock - MSN
There's No Escaping Ardelyx, Inc.'s (NASDAQ:ARDX) Muted Revenues - Simply Wall St
Ardelyx spikes as chairman buys nearly $1M worth of stock - MSN
Ardelyx (ARDX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
(ARDX) Technical Data - Stock Traders Daily
Ardelyx (ARDX) Earnings Expected to Grow: Should You Buy? - Nasdaq
Ardelyx, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your RightsARDX - ACCESS Newswire
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Shareholders that lost money on Ardelyx, Inc.(ARDX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
ARDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ardelyx, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
State Street Corp Reduces Stake in Ardelyx Inc: Analyzing the Im - GuruFocus.com
Ardelyx (NASDAQ:ARDX) Upgraded to "Strong-Buy" at Cantor Fitzgerald - MarketBeat
Ardelyx, Inc. (NASDAQ:ARDX) CEO Michael Raab Sells 41,666 Shares - MarketBeat
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ardelyx Inc Stock (ARDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Renz Justin A | Chief Financial Officer |
Feb 20 '25 |
Sale |
5.62 |
5,171 |
29,077 |
285,968 |
| RAAB MICHAEL | President & CEO |
Feb 20 '25 |
Sale |
5.62 |
22,964 |
129,124 |
1,085,755 |
| GRAMMER ELIZABETH A | See Remarks |
Feb 20 '25 |
Sale |
5.62 |
4,291 |
24,128 |
181,043 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):